Physician profile
Caitlin Danos
NPI 1750183042
$1,938.42
in general payments reported to CMS, 2019-2025
13 companies · $1,938 in 2025
The $1,938 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,788 · Education: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,787.74 |
| Education | $150.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $442.19 | 2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $375.90 | 2025 | Tezspire, Fasenra, Breztri |
| Csl Behring | $290.97 | 2025 | Andembry, Hizentra, Haegarda |
| Ars Pharmaceuticals Operations, INC. | $265.32 | 2025 | Neffy |
| Pharming Healthcare, INC. | $168.22 | 2025 | Ruconest |
| Novartis Pharmaceuticals Corporation | $104.27 | 2025 | |
| Glaxosmithkline, LLC. | $79.09 | 2025 | Nucala, Trelegy Ellipta |
| Biocryst US Sales Co., LLC | $54.59 | 2025 | Orladeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $47.17 | 2025 | Cuvitru |
| Verona Pharma, INC. | $45.65 | 2025 | Ohtuvayre |
| Blueprint Medicines Corporation | $23.98 | 2025 | Ayvakit |
| Genentech USA, INC. | $22.20 | 2025 | Xolair |
| Amgen INC. | $18.87 | 2025 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Danos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.